- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00931034
Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women
June 30, 2009 updated by: Mondelēz International, Inc.
The Effect of South Beach Diet™ Using South Beach Diet™ Products Compared to the American Diabetic Association Diabetes Meal Plan on Body Weight and Satiety in Overweight Diabetic Women
The purpose of this study is to examine the effectiveness of the South Beach Diet and products compared to the American Diabetic Association Diabetes Meal Plan.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Northridge, California, United States, 91325
- Medicus Research
-
-
Florida
-
Bradenton, Florida, United States, 34205
- SIBR Research
-
Miami, Florida, United States, 33143
- Miami Research Associates
-
-
Nevada
-
Las Vegas, Nevada, United States, 89101
- Nevada Alliance Against Diabetes
-
-
New York
-
Rochester, New York, United States, 14609
- Rochester Clinical Research Inc
-
-
Virginia
-
Virginia Beach, Virginia, United States, 23455
- Chase Wellness & Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female age 18 to 55 years
- Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result
- Healthy as determined by laboratory results and medical history
- Waist circumference > 87 cm
- Stable weight defined as < 4.5 kg gained or lost in past year
- Agreement to maintain current level of physical activity throughout the study
- Diagnosed with Type II diabetes mellitus with fasting blood glucose 100 - 250 mg/dl (5.6 - 13.9 mmol/L)
- Ability to comprehend and complete the questionnaires and forms
- Agreement to comply with study procedures, test article consumption, and has access to a microwave oven
- Voluntary, written, informed consent to participate in the study
Exclusion Criteria:
- Pregnant, breastfeeding, or planning to become pregnant during the course of the trial
Use of prescription or over the counter products known to effect weight including but not limited to the following:
- megestrol acetate;
- somatropin;
- sibutramine;
- orlistat;
- paroxetine;
- dextroamphetamine;
- methylphenidate;
- atomoxetine;
- quetiapine;
- olanzepine;
- risperidone, within 4 weeks of randomization and during the trial
- Unstable medication for diabetes mellitus (Dosage must be stable for 90 days prior to randomization), use of insulin is exclusionary
- Alcohol use > 2 standard alcoholic drinks per day
Significant cardiac history defined as a history of:
- myocardial infarction (MI);
- coronary angioplasty or bypass graft(s);
- valvular disease or repair;
- unstable angina pectoris;
- transient ischemic attack (TIA);
- cerebrovascular accidents (CVA);
- congestive heart failure; or
- coronary artery disease (CAD)
- History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission for more than 5 years are acceptable.
- Uncontrolled hypertension defined as untreated systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg
- Unstable renal and/or liver disease
- History of alcohol or drug abuse within the past year
- Unstable psychiatric disorder requiring hospitalization within the past 6 months
- Immunocompromised individuals such as subjects that have undergone organ transplantation or subjects diagnosed with human immunodeficiency virus (HIV)
- History of hemoglobinopathies such as sickle cell anemia or thalassemia, sideroblastic anemia
- Participation in another clinical research trial within 30 days prior to randomization and during the trial
- Significant abnormal liver function as defined as AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN
- Serum creatinine > 125 umol/L
- Anemia of any etiology defined as hemoglobin < 110 g/L
- Uncontrolled and/or untreated thyroid disorder
- Unstable medications (Dosage must be stable for 90 days prior to randomization)
- History of food allergies or sensitivities, including lactose intolerance
- Vegetarians
- Cognitively impaired and/or unable to give informed consent
- Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: South Beach Diet with SBD Products
|
|
ACTIVE_COMPARATOR: ADA Diabetes meal plan
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in body weight from baseline to week 24
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the satiety response to the individual diets
Time Frame: 24 weeks
|
24 weeks
|
Analyze circumference measurements & body composition; blood glucose, HbA1c, insulin, lipid profile, blood pressure & questionnaire responses on food cravings and quality of life
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: David Crowley, MD, KGK Science Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (ACTUAL)
April 1, 2008
Study Completion (ACTUAL)
July 1, 2008
Study Registration Dates
First Submitted
June 29, 2009
First Submitted That Met QC Criteria
June 30, 2009
First Posted (ESTIMATE)
July 2, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
July 2, 2009
Last Update Submitted That Met QC Criteria
June 30, 2009
Last Verified
June 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07SWHK
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Free, Inc.Not yet recruitingDiabetes Mellitus Type 2 - Insulin-Treated
Clinical Trials on South Beach Diet with South Beach Diet Products
-
Mondelēz International, Inc.KGK Science Inc.CompletedEffect of South Beach Diet (SBD™) Using SBD™ Products Compared to a Calorie-Restricted Diet in WomenOverweightUnited States
-
Bagel, Jerry, M.D.Food and Drug Administration (FDA)CompletedPsoriasis | Weight Loss | DietUnited States
-
Wageningen UniversityRecruitingBlood Pressure | Cardiometabolic HealthNetherlands
-
Clinica Universidad de Navarra, Universidad de...Rovi Pharmaceuticals Laboratories; Equipe EnervitCompletedOverweight | Type-2 DiabetesSpain
-
Henning BliddalCambridge Weight Plan Limited; Oak Foundation; The Danish Rheumatism AssociationCompleted